Shirai K - Search Results

1

A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma.

Hasanov M, Rioth MJ, Kendra K, Hernandez-Aya L, Joseph RW, Williamson S, Chandra S, Shirai K, Turner CD, Lewis K, Crowley E, Moscow J, Carter B, Patel S. Hasanov M, et al. Among authors: shirai k. Cancers (Basel). 2020 Aug 13;12(8):2270. doi: 10.3390/cancers12082270. Cancers (Basel). 2020. PMID: 32823698 Free PMC article.

2

Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma.

In GK, Nallagangula A, Choi JS, Tachiki L, Blackburn MJ, Capone S, Bollin KB, Reuben DY, Shirai K, Zhang-Nunes S, Ragab O, Terando A, Hu JC, Lee H, Bhatia S, Chandra S, Lutzky J, Gibney GT. In GK, et al. Among authors: shirai k. J Immunother Cancer. 2022 May;10(5):e004839. doi: 10.1136/jitc-2022-004839. J Immunother Cancer. 2022. PMID: 35545318 Free PMC article.

3

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.

Afzal MZ, Mabaera R, Shirai K. Afzal MZ, et al. Among authors: shirai k. J Immunother Cancer. 2018 Feb 12;6(1):13. doi: 10.1186/s40425-018-0322-1. J Immunother Cancer. 2018. PMID: 29433557 Free PMC article.

4

Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.

Afzal MZ, Shirai K. Afzal MZ, et al. Among authors: shirai k. Melanoma Res. 2018 Aug;28(4):341-347. doi: 10.1097/CMR.0000000000000459. Melanoma Res. 2018. PMID: 29750753

5

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.

Afzal MZ, Mercado RR, Shirai K. Afzal MZ, et al. Among authors: shirai k. J Immunother Cancer. 2018 Jul 2;6(1):64. doi: 10.1186/s40425-018-0375-1. J Immunother Cancer. 2018. PMID: 29966520 Free PMC article.

6

Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors.

Cao Y, Afzal MZ, Shirai K. Cao Y, et al. Among authors: shirai k. J Thorac Dis. 2021 Aug;13(8):4668-4677. doi: 10.21037/jtd-21-150. J Thorac Dis. 2021. PMID: 34527308 Free PMC article.

7

Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis.

Chang R, Shirai K. Chang R, et al. Among authors: shirai k. BMJ Case Rep. 2016 Sep 22;2016:bcr2016216426. doi: 10.1136/bcr-2016-216426. BMJ Case Rep. 2016. PMID: 27659911 Free PMC article.

8

A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer.

Afzal MZ, Dragnev K, Shirai K. Afzal MZ, et al. Among authors: shirai k. J Thorac Dis. 2018 Jun;10(6):3575-3584. doi: 10.21037/jtd.2018.06.08. J Thorac Dis. 2018. PMID: 30069355 Free PMC article.

9

Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors.

Afzal MZ, Sarwar T, Shirai K. Afzal MZ, et al. Among authors: shirai k. J Immunother. 2019 Sep;42(7):251-264. doi: 10.1097/CJI.0000000000000272. J Immunother. 2019. PMID: 31145229

10

Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors.

Afzal MZ, Dragnev K, Sarwar T, Shirai K. Afzal MZ, et al. Among authors: shirai k. Lung Cancer Manag. 2019 May 7;8(2):LMT11. doi: 10.2217/lmt-2018-0016. eCollection 2019 Oct. Lung Cancer Manag. 2019. PMID: 31645894 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,211 results

Search Page